For Immediate Release: June 9, 2017
513-579-9911 x 12523
Dr. Gregory Hale Joins Medpace as Senior Medical Director
CINCINNATI, OH — (June 9, 2017) – Medpace (MEDP), a scientifically-driven, global full-service clinical research organization (CRO), announced that Gregory Hale has joined Medpace as Senior Medical Director of Medical Affairs. Dr. Hale is an experienced physician with clinical expertise in bone marrow transplantation, cellular therapies, and hematologic malignancies. With the addition of Dr. Hale, Medpace further strengthens its capabilities across the full range of solid and hematologic malignancies.
About Gregory Hale, MD
Dr. Gregory Hale earned his medical degree from the Joan C. Edwards School of Medicine at Marshall University. He completed post-doctoral training at Children’s Hospital of Pittsburgh and completed fellowship training in pediatric hematology and oncology at St. Jude Children’s Research Hospital in Memphis, Tennessee. Prior to joining Medpace, he held a variety of director level roles at nationally recognized academic institutions where he served as a principal investigator for clinical trials of novel medications and cellular therapies, including gene-modified cellular therapies. He has served as Clinical Director of the Transplant and Gene Therapy Program at St. Jude Children’s Research Hospital, and was a member of the Blood and Marrow Transplant Program at the University of Kentucky. Most recently he was Professor of Oncology and Pediatrics at Johns Hopkins University School of Medicine at Johns Hopkins All Children’s Hospital. He has served at a national leadership level in positions for the National Marrow Donor Program, the Foundations for the Accreditation of Cellular Therapies, the American Academy of Pediatrics, and the Bone Marrow Foundation. Dr. Hale has also served as an invited expert reviewer for the FDA Cellular, Tissue and Gene Therapies Advisory Committee and serves as Co-Chair of the Pediatric Cancer Working Committee for the Center for International Blood and Marrow Transplant research. He is an internationally recognized clinical researcher with more than 200 peer-reviewed manuscripts, book chapters, and review articles.
Medpace is a scientifically-driven, global full-service clinical research organization (CRO) providing Phase I-IV clinical development services for drug, biologic, and device programs. Medpace’s physician-led, high-science, and disciplined operating approach leverages regulatory and therapeutic expertise to accelerate the global development of safe and effective medical therapeutics across all major areas including hematology and oncology, cardiovascular, metabolic/diabetes, infectious diseases, and neurology and psychiatry.